Dicerna Pharmaceuticals Inc Uncategorized Contracts & Agreements

Royalty Acquisition Agreement by and between the Company and Royalty Pharma PLC, dated as of April 8, 2021 (Filed With SEC on May 6, 2021)

Patent Cross-License Agreement by and between the Company and Alnylam Pharmaceuticals, Inc., dated as of April 3, 2020 (Filed With SEC on August 6, 2020)

Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (Filed With SEC on February 28, 2020)

Additional Target Agreement, dated December 31, 2018, by and between the Company and Boehringer Ingelheim International GmbH (Filed With SEC on March 13, 2019)

See Restrictive Legends on Reverse Side of Certificate Incorporated Under the Laws of the State of Delaware (Filed With SEC on March 30, 2017)

[Remainder of Page Intentionally Left Blank] -2- (Filed With SEC on March 30, 2017)

******* (Filed With SEC on March 10, 2016)

DICERNA PHARMACEUTICALS, INC. 2016 INDUCEMENT PLAN (Filed With SEC on March 10, 2016)

LICENSEAGREEMENT by and between DICERNA PHARMACEUTICALS, INC., on the one hand, and PROTIVA BIOTHERAPEUTICS INC. and TEKMIRA PHARMACEUTICALS CORPORATION on the other hand... (Filed With SEC on March 12, 2015)

COMMERCIAL LICENCE AGREEMENT (Filed With SEC on January 28, 2014)

[Company Letterhead] (Filed With SEC on January 28, 2014)

EMPLOYMENTAGREEMENT (Filed With SEC on December 31, 2013)

DICERNA PHARMACEUTICALS, INC. 480 Arsenal Street Building 1, Suite 120 Watertown, MA 02472 (Filed With SEC on December 31, 2013)

DICERNA PHARMACEUTICALS, INC. 480 Arsenal Street Building 1, Suite 120 Watertown, MA 02472 February 28, 2011 (Filed With SEC on December 31, 2013)

COMMERCIAL LICENCE AGREEMENT (Filed With SEC on December 31, 2013)